AMGN241004P210000
- 0.01
- 0.000.00%
Amgen Newsroom
Roche Sees Carmot Obesity Drugs' Potential Peak Sales at $3.6B+: Report
Amgen Inc. (AMGN): Hedge Fund Interest and Strong Pipeline Support Moderate Buy Rating
Novo Nordisk's Ozempic, Regeneron/Sanofi's Dupixent Set to Advance in Top Drug Sales
Institutional Investors May Overlook Amgen Inc.'s (NASDAQ:AMGN) Recent US$7.9b Market Cap Drop as Long-term Gains Remain Positive
Here Are the Medicare Part D Drugs Expected to Face 2025 Price Negotiations
Notable Analyst Calls This Week: Microsoft, Starbucks and GM Among Top Picks
Federman & Sherwood Investigates Amgen, Inc. for Data Breach
Chevron, Visa Share Gains Contribute To Dow's Nearly 325-Point Climb
Cantor Highly Bullish on Amgen Obesity Drug, Starts Coverage at Overweight
Cantor Fitzgerald Initiates Amgen(AMGN.US) With Buy Rating, Announces Target Price $405
Amgen Inc. (AMGN): An Undervalued Wide Moat Stock to Buy According to Analysts
AMGN Stock Falls Despite Upbeat Data on Immunology Drugs: Here's Why
RBC Capital Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $362
Dow, S&P 500 Retreat From Record Highs
Amgen Stock Slides 5% as Analysts Weigh in on Drug Study Results
Amgen Stock Slips 3% Following Phase 3 Data for Rocatinlimab, Uplizna
Analyst Expectations For Amgen's Future
Equities Mostly Fall Intraday as Traders Weigh Macro Data
Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs
BioAge, Obesity Drug Developer, Upsizes Proposed IPO